Is a shortage of hydroxychloroquine the next crisis?
Data from Asia and Europe suggests that hydroxychloroquine may be a useful agent in the fight against COVID-19.  It is being discussed in evening news programs and was mentioned by President Trump during an afternoon press conference on March 19.  We are hearing that the commercial tablets and bulk API are all on back order through the middle of April. Compounders can be instrumental in supporting patient access to hydroxychloroquine, provided we can source the API, which right now is difficult.
 
APC is working with our industry partners to create a roadmap for addressing this issue, and we'll be reaching out to FDA soon. Stay tuned for more info - and if you have ideas or intel, contact scott@a4pc.org.
APC is the voice for pharmacy compounding, representing compounding pharmacists, technicians, educators, students, researchers and suppliers. Compounding exists for patients and animals who are not served by traditional pharmaceutical manufacturers. Every day, APC members play a critical, often life-or-death role in patients' lives, creating essential medications unavailable elsewhere for a range of issues, including autism, oncology, dermatology, ophthalmology, pediatrics, women's health, and others.  Learn more at www.a4pc.org.